Facing head and neck cancer deaths head on: Lessons for survival
Author:
Open Access
Abstract
Despite making up only 3% of all cancers, squamous cell carcinomas of the head and neck (HNC) exemplify complex survivorship care. Characteristics of this cohort of patients include high levels of comorbidity, high baseline risk of psychosocial distress, and exposure to highly toxic treatment strategies. With survival rates of the primary cancer increasing over time, the population at risk for secondary complications (including recurrence, secondary primaries, illnesses induced by risk factors, and injuries related to treatment) is increasing. Recognition of elevated death rates of survivors, persisting up to 10 years after diagnosis, outline the importance of a dedicated approach to HNC survivorship care, whether provided within or outside the comprehensive cancer center.Keywords
This publication has 12 references indexed in Scilit:
- Outcomes toolbox for head and neck cancer researchHead & Neck, 2015
- Causes of death in long‐term survivors of head and neck cancerCancer, 2014
- Nasopharyngeal cancer: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2012
- Cancer Survivorship Research: A Review of the Literature and Summary of Current NCI-Designated Cancer Center ProjectsCancer Epidemiology, Biomarkers & Prevention, 2011
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningNew England Journal of Medicine, 2011
- Conditional relative survival in head and neck squamous cell carcinoma: Permanent excess mortality risk for long‐term survivorsHead & Neck, 2010
- Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st Century: A Period AnalysisThe Oncologist, 2010
- Human Papillomavirus and Survival of Patients with Oropharyngeal CancerNew England Journal of Medicine, 2010
- Squamous cell carcinoma of the head and neck: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2010
- TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology GroupThe Lancet Oncology, 2007